Abstract
- Background: Coronary artery disease in patients with atrial fibrillation is one of the quite complex clinical situations. The overlap between atrial fibrillation and PCI implies challenges related to the management of antithrombotic therapy.
- Objective: To study the current status of using antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention; describe the incidence of major complications (including thrombus and bleeding) during 6 months of follow-up.
- Subjects and Methods: The study was conducted on patients with non-valvular atrial fibrillation who underwent percutaneous coronary intervention at the Vietnam National Heart Institute, Bach Mai Hospital and Nghe An Friendship General Hospital from January, 2020 to December, 2022 using a retrospective method, and a prospective study with follow-up of up to 6 months after discharge.
- Results: The study was conducted on 174 patients, with 45.4% of patients using dual antithrombotic therapy (DAT: using 1 antiplatelet agent combined with 1 anticoagulant); 54.6% of patients used triple antithrombotic therapy (TAT: using dual antiplatelet therapy combined with 1 anticoagulant). The most common antiplatelet drug was clopidogrel at 95.4%. In the study group, the most commonly used anticoagulant was rivaroxaban at 67.2%; followed by vitamin K antagonist (Acenocoumarol) at 12.6%.
- Conclusion: The rate of using triple antithrombotic therapy was higher than dual antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention. Bleeding events in patients using TAT regimen were higher than those using DAT regimen (p<0.05).